In order to achieve these goals we not only need effective and safe drugs but also the appropriate study designs to really detect the most relevant outcomes [2, 7].doi:10.1007/s00415-008-6012-zP. RieckmannJourna
Multiple sclerosis (MS) is the most common chronic inflammatory, demyelinating and neurodegenerative disease of the central nervous system in young adults. This disorder is a heterogeneous, multifactorial, immune-mediated disease that is influenced by both genetic and environmental factors. In most patien...
The most common sites of multiple sclerosis are periventricular, proximal cortex, optic nerve, spinal cord, brainstem and cerebellum. The main clinical features of multiple lesions are dissemination of lesions in space and in time. The main clinical features of the disease are scattered white matter...
Multiple sclerosis (MS) has a female predominance and typically develops at young age with a peak incidence between 20 and 40 years [1]. Clinically, it is characterized by a large variability of symptoms arising from focal inflammation of the central nervous system that may occur at various poi...
Although clinical trials in multiple sclerosis are extremely difficult to conduct because of the unpredictable course of the disease and the problem of defining and monitoring disease activity, some controlled and several uncontrolled studies suggest that global immunosuppression may result in a small but...
et al. Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis. Brain 143, 3013–3024 (2020). Article PubMed Google Scholar Rollot, F. et al. Cumulative effects of therapies on disability in relapsing multiple sclerosis. Mult. Scler. J. 27, 1760–1770 (2021...
Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. An actress's announcement that she is in remission from multiple sclerosis (MS), along with significant new treatment research, resulted in this week's top trending clinical topic. Selma Blair, 49, who was...
Despite the onset of new oral medications, injectable multiple sclerosis drugs are expected to have a higher demand during the forecast period. Thus, in terms of route of administration, the parenteral segment of the multiple sclerosis drugs market is expected to reach a market value ofUS$ 12.7...
Outline Abstract Keywords 1. Multiple sclerosis (MS) 2. Hygiene hypothesis 3. Helminth therapy in MS 4. The way forward 5. Conclusions Acknowledgements ReferencesShow full outline Cited by (73) Figures (3) Tables (2) Table 1 Table 2
drugs that target these multiple disease processes in tandem. These findings also question our preconceptions of multiple sclerosis as a two-stage disease, and instead suggest that neurodegenerative processes are present early in the disease course, which may be interwoven with inflammation, and crucial...